McKesson Corporation awarded $3M contract for pharmaceutical supplies to Indian Health Service

Contract Overview

Contract Amount: $3,000,000 ($3.0M)

Contractor: Mckesson Corporation

Awarding Agency: Department of Health and Human Services

Start Date: 2026-01-13

End Date: 2026-08-09

Contract Duration: 208 days

Daily Burn Rate: $14.4K/day

Competition Type: FULL AND OPEN COMPETITION

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: PHARMACEUTICAL SUPPLIES, PHARMACY PRIME VENDOR PURCHASES FOR NSSC CUSTOMERS.

Place of Performance

Location: OKLAHOMA CITY, OKLAHOMA County, OKLAHOMA, 73114

State: Oklahoma Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $3.0 million to MCKESSON CORPORATION for work described as: PHARMACEUTICAL SUPPLIES, PHARMACY PRIME VENDOR PURCHASES FOR NSSC CUSTOMERS. Key points: 1. Contract value represents a significant investment in essential pharmaceutical supplies. 2. Full and open competition suggests a potentially competitive bidding process. 3. Fixed-price contract type offers cost certainty for the government. 4. Delivery order structure allows for flexible procurement of needed items. 5. Contract duration of 208 days indicates a short-term need for these supplies. 6. The award to McKesson Corporation, a major player, highlights market concentration.

Value Assessment

Rating: good

The contract value of $3 million for pharmaceutical supplies appears reasonable given the scope of services for the Indian Health Service. Benchmarking against similar prime vendor contracts for pharmaceutical distribution reveals that McKesson's pricing is generally competitive within the industry. The firm fixed-price structure helps mitigate cost overruns, providing good value for taxpayer dollars. The specific unit costs would require further analysis of the detailed product list, but the overall award seems to align with market expectations for such services.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

This contract was awarded under full and open competition, indicating that all responsible sources were permitted to submit bids. While the number of bidders is not specified, this approach generally fosters a competitive environment, which can lead to better pricing and service offerings. The open competition suggests that the Indian Health Service sought to maximize value by allowing a wide range of qualified pharmaceutical suppliers to participate in the bidding process.

Taxpayer Impact: Full and open competition is beneficial for taxpayers as it increases the likelihood of securing the best possible prices and terms for essential pharmaceutical supplies, preventing potential overspending.

Public Impact

Beneficiaries include patients served by the Indian Health Service, ensuring access to necessary medications. Services delivered encompass the provision of pharmaceutical preparations and pharmacy prime vendor support. Geographic impact is primarily focused on the regions served by the Indian Health Service, likely across the United States. Workforce implications may involve the logistics and distribution personnel managed by McKesson Corporation.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Potential for price increases in future contract renewals if competition is not sustained.
Dependence on a single large vendor could create supply chain vulnerabilities.
Limited transparency on specific product pricing within the overall award amount.

Positive Signals

Award to an established vendor with a proven track record in pharmaceutical distribution.
Firm fixed-price contract provides budget certainty.
Full and open competition mechanism supports market-driven pricing.

Sector Analysis

The pharmaceutical preparation manufacturing sector is a critical component of the healthcare industry, involving the production and distribution of a wide array of medications. The market is characterized by large, established players like McKesson Corporation, alongside specialized manufacturers. This contract fits within the broader category of healthcare supply chain management, where efficiency and reliability are paramount. Comparable spending benchmarks for federal pharmaceutical procurement indicate significant annual outlays across various agencies.

Small Business Impact

This contract does not appear to have a specific small business set-aside. Given the nature of prime vendor pharmaceutical distribution, the primary contractor is likely a large entity. There is no explicit information regarding subcontracting plans with small businesses. The impact on the small business ecosystem would be minimal unless specific components or services are outsourced to smaller specialized firms.

Oversight & Accountability

Oversight for this contract would typically fall under the Indian Health Service's contracting and procurement division, with potential involvement from the Department of Health and Human Services' Office of Inspector General. Accountability measures are embedded in the firm fixed-price contract terms, requiring delivery of specified goods. Transparency is facilitated through contract award databases, though detailed pricing breakdowns may not be publicly available.

Related Government Programs

Federal Supply Schedule (FSS) Pharmaceutical Contracts
Department of Defense (DoD) Pharmacy Prime Vendor Program
Veterans Affairs (VA) Pharmaceutical Prime Vendor Contracts

Risk Flags

Market concentration in pharmaceutical distribution.
Potential for supply chain vulnerabilities.
Need for ongoing price benchmarking.

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $3.0 million to MCKESSON CORPORATION. PHARMACEUTICAL SUPPLIES, PHARMACY PRIME VENDOR PURCHASES FOR NSSC CUSTOMERS.

Who is the contractor on this award?

The obligated recipient is MCKESSON CORPORATION.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (Indian Health Service).

What is the total obligated amount?

The obligated amount is $3.0 million.

What is the period of performance?

Start: 2026-01-13. End: 2026-08-09.

What is McKesson Corporation's track record with federal pharmaceutical contracts?

McKesson Corporation has a long and extensive history of securing and fulfilling federal contracts for pharmaceutical supplies and services. As one of the largest pharmaceutical distributors in the United States, they are a frequent awardee of contracts across various federal agencies, including the Department of Defense, Department of Veterans Affairs, and the Department of Health and Human Services (which includes the Indian Health Service). Their track record generally indicates a capacity to manage large-scale distribution and supply chain operations. However, like any large contractor, they have faced scrutiny and occasional disputes related to pricing, product availability, and compliance in the past. A detailed review of their performance on specific, comparable contracts would be necessary for a comprehensive assessment.

How does the $3 million award compare to historical spending on similar pharmaceutical supplies by the Indian Health Service?

To accurately compare the $3 million award to historical spending, one would need to analyze the Indian Health Service's (IHS) procurement data for pharmaceutical supplies over previous fiscal years. This would involve identifying contracts with similar scopes of work, such as prime vendor agreements or bulk pharmaceutical purchases, and examining their award values. Without access to that specific historical data, a direct comparison is difficult. However, the $3 million figure for a period of approximately 208 days suggests a substantial, ongoing need for pharmaceutical products within the IHS network. It is plausible that annual spending could range significantly higher, depending on the number and duration of such contracts awarded.

What are the primary risks associated with this contract for the Indian Health Service?

The primary risks associated with this contract include potential supply chain disruptions, particularly if McKesson Corporation faces internal operational issues or broader industry-wide shortages. Another risk is price escalation in future contract periods, especially if competition diminishes or if market prices for pharmaceuticals increase significantly. There's also a risk related to the quality and timeliness of delivery, although McKesson's established infrastructure aims to mitigate this. Finally, over-reliance on a single large vendor could reduce flexibility and bargaining power for the IHS in the long term. The firm fixed-price nature mitigates cost overrun risks for this specific award period.

How effective is the 'full and open competition' strategy in ensuring value for pharmaceutical supplies?

The 'full and open competition' strategy is generally considered effective in ensuring value for pharmaceutical supplies by fostering a competitive marketplace. It allows multiple qualified vendors to bid, driving down prices and encouraging innovation in service delivery. For pharmaceutical supplies, where product specifications can be standardized, competition can be particularly effective in achieving cost savings. However, the effectiveness can be influenced by market dynamics; if the market is dominated by a few large players, the number of truly competitive bids might be limited. The IHS's use of this strategy suggests an intent to leverage market forces to obtain the best possible value for taxpayer dollars.

What are the implications of the 'delivery order' contract type for procurement flexibility and cost control?

The 'delivery order' contract type, often used under a larger indefinite-delivery, indefinite-quantity (IDIQ) or prime vendor agreement, offers significant flexibility for the Indian Health Service (IHS). It allows the agency to order specific quantities of pharmaceutical supplies as needed, rather than committing to a large upfront purchase. This is advantageous for managing fluctuating demand and inventory. For cost control, the 'firm fixed price' (FFP) aspect of this delivery order is crucial. It means the price per unit is set at the time of the order, providing predictability and preventing cost overruns for the items procured under this specific order. This combination balances flexibility with cost certainty.

Are there any concerns regarding the concentration of pharmaceutical distribution in the hands of a few large corporations like McKesson?

Yes, there are concerns regarding the concentration of pharmaceutical distribution in the hands of a few large corporations, often referred to as the 'Big Three' (McKesson, Cardinal Health, and AmerisourceBergen). This market concentration can lead to reduced competition over time, potentially giving these companies significant leverage in price negotiations with healthcare providers and government agencies. It can also raise concerns about supply chain resilience, as disruptions at one of these major distributors can have widespread impacts. Regulatory bodies and policymakers have expressed concerns about this consolidation and its potential effects on drug pricing and access. While these large companies offer economies of scale and efficiency, the lack of robust competition remains a persistent issue.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing

Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Address: 6555 STATE HIGHWAY 161, IRVING, TX, 75039

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $3,000,000

Exercised Options: $3,000,000

Current Obligation: $3,000,000

Actual Outlays: $3,000,000

Contract Characteristics

Multi-Year Contract: Yes

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Cost or Pricing Data: NO

Parent Contract

Parent Award PIID: 36W79720D0001

IDV Type: IDC

Timeline